Anktiva plus checkpoint inhibitor therapy demonstrated statistically significant immune restoration across two clinical ...

Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an ...

QUILT-3.055 is a basket trial evaluating nogapendekin alfa inbakicept across multiple solid tumor types. In the NSCLC cohort, ...

As the renal cell carcinoma (RCC) treatment landscape shifts to more personalized and combinatorial approaches, advanced practice providers (APPs) are key to the safety of patients receiving tyrosine ...

Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the ...

ImmunityBio, Inc. , a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA (nogapendekin alfa inbakicept) clinical program in non-small cell lung cancer (NSCLC) ...

Nivolumab is a monoclonal antibody-based immunotherapy used in the treatment of several cancers, including lung and head-and-neck cancers| Business News ...

The availability of a more affordable biosimilar is expected to improve access to advanced cancer treatment not just in major ...

The Delhi HC ruling does not abolish patents or endorse blanket early entry. Instead, it stresses courts may intervene ...

The Delhi High Court has allowed Zydus Lifesciences to sell its nivolumab biosimilar, citing public interest, while directing ...

As someone who's followed the evolution of cancer treatments closely—both personally, having supported loved ones through their battles, and professionally in the pharmaceutical space—I've been ...

Elephas Biosciences Corporation (Elephas), a private company that has developed an innovative live tissue platform for immunotherapy response prediction, announced today the expansion of its ...